Bluebird Bio Inc. (NASDAQ:BLUE) has earned an average rating of “Buy” from the eighteen ratings firms that are currently covering the stock. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation, twelve have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $92.03.
A number of research analysts recently issued reports on BLUE shares. Maxim Group restated a “buy” rating and set a $85.00 price objective on shares of Bluebird Bio in a research report on Monday, September 12th. Cowen and Company restated an “outperform” rating on shares of Bluebird Bio in a research report on Friday, September 9th. Wedbush reiterated an “outperform” rating and set a $117.00 price target on shares of Bluebird Bio in a research report on Monday, October 3rd. Zacks Investment Research lowered Bluebird Bio from a “hold” rating to a “sell” rating in a research report on Wednesday. Finally, Roth Capital started coverage on Bluebird Bio in a research report on Thursday, September 22nd. They set a “buy” rating and a $87.00 price target for the company.
In other news, insider David Davidson sold 1,000 shares of the company’s stock in a transaction on Friday, July 15th. The stock was sold at an average price of $45.08, for a total transaction of $45,080.00. Following the completion of the sale, the insider now directly owns 10,600 shares of the company’s stock, valued at $477,848. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Eric Sullivan sold 2,807 shares of the company’s stock in a transaction on Wednesday, July 20th. The shares were sold at an average price of $45.04, for a total value of $126,427.28. Following the sale, the insider now directly owns 4,656 shares of the company’s stock, valued at $209,706.24. The disclosure for this sale can be found here. Insiders own 3.50% of the company’s stock.
Large investors have recently made changes to their positions in the stock. Wellington Management Group LLP bought a new stake in shares of Bluebird Bio during the first quarter valued at approximately $51,095,000. BlackRock Fund Advisors increased its stake in shares of Bluebird Bio by 80.0% in the second quarter. BlackRock Fund Advisors now owns 1,386,229 shares of the company’s stock valued at $60,010,000 after buying an additional 616,095 shares in the last quarter. State Street Corp increased its stake in shares of Bluebird Bio by 41.4% in the second quarter. State Street Corp now owns 1,699,977 shares of the company’s stock valued at $73,592,000 after buying an additional 498,041 shares in the last quarter. RTW Investments LLC increased its stake in shares of Bluebird Bio by 170.4% in the second quarter. RTW Investments LLC now owns 612,025 shares of the company’s stock valued at $26,495,000 after buying an additional 385,654 shares in the last quarter. Finally, Deerfield Management Co. bought a new stake in shares of Bluebird Bio during the second quarter valued at approximately $14,636,000.
Shares of Bluebird Bio (NASDAQ:BLUE) opened at 69.67 on Wednesday. The firm’s market cap is $2.59 billion. Bluebird Bio has a 1-year low of $35.37 and a 1-year high of $99.70. The company’s 50 day moving average price is $61.78 and its 200-day moving average price is $50.12.
Bluebird Bio (NASDAQ:BLUE) last released its quarterly earnings data on Wednesday, August 3rd. The company reported ($1.59) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.44) by $0.15. Bluebird Bio had a negative net margin of 3,512.13% and a negative return on equity of 24.85%. The company had revenue of $1.55 million for the quarter, compared to analyst estimates of $2.01 million. During the same quarter in the prior year, the firm earned ($1.57) EPS. The company’s revenue for the quarter was down 68.6% compared to the same quarter last year. Equities analysts expect that Bluebird Bio will post ($6.19) EPS for the current fiscal year.
About Bluebird Bio
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Receive News & Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.